We have obtained instituitional review board approval for our Mexican ibogaine outcome study. Principal investigator John Harrison, PsyD candidate at the California Institute of Integral Studies (CIIS), received a letter from the Human Research Review Committee of CIIS granting final approval. We officially startedt our investigation into the short and longer-term outcomes of ibogaine treatment for opiate addiction. The study will follow 30 patients who undergo ibogaine therapy at the Pangea Biomedics Ibogaine Association in Playas De Tijuana, Mexico for one year after their treatment. The budget to conduct this study is estimated to be about $30,000, all of which remains to be raised. Source

The FDA issued a letter saying that we had successfully resolved all the outstanding issues in our Investigative New Drug application (#101,825) to evaluate LSD-assisted psychotherapy in our Swiss end-of-life/anxiety pilot study (PDF). FDA is now open to the possibility of the therapeutic potential of LSD-assisted psychotherapy and will accept data from our Swiss study. The budget for our Swiss LSD/end-of-life anxiety study is $225,000. Weve raised about $125,000 and are still seeking the final $100,000. Source